IFNG and macrophage activation syndrome: There were positive results in a pilot study of emapalumab (IFN-gamma inhibitor) for the treatment of refractory MAS, and beneficial results with combination biologics and Janus kinase (JAK) inhibitors for refractory Still’s arthritis.